Skip to content

Tiludronate

    Discontinued

    DEA Class; Rx

    Common Brand Names; Skelid

    • Calcium Metabolism Modifiers; 
    • Bisphosphonate Derivatives

    Bisphosphanate that inhibits bone resorption via actions on osteoclast activity, leading to an indirect increase in bone formation

    Indicated for the treatment of Paget’s Disease

    Hypersensitivity

    Inability to stand or sit upright for at least 30 minutes

    Abnormalities of the esophagus which delay emptying such as stricture or achalasia

    Hypocalcemia

    • Dizziness (4%)
    • Edema (2.7%)
    • Insomnia
    • Flushing
    • Hypertension
    • Chest pain
    • Back pain
    • Musculoskeletal pain
    • Diarrhea
    • Dyspepsia
    • Flushing
    • Headache
    • Nausea
    • Rhinitis
    • Sinusitis
    • URI

    Risk of esophageal adverse effects, including esophagitis, esophageal ulceration/erosion, or esophageal bleeding with strictures or perforation

    Following therapy, allow 3 months interval to assess response

    Not recommended in severe renal failure (CrCl <30 mL/min)

    Take with plain water only-NOT coffee, juice or mineral water; sit or stand upright for at least 30 minutes after administration

    Risk of osteonecrosis of jaw

    Food reduces bioavailability

    Risk of severe bone, joint &/or muscle pain

    Avoid concurrent multivalent cation-containing medicines or food

    Pregnancy Category: C

    Lactation: not known if crosses in to breast milk, use caution

    Adults

    Paget’s Disease

    400 mg PO qDay for 3 months

    Renal Impairment

    ClCr< 30 mL/min: Not recommended

    Not removed by dialysis

    tiludronate (Discontinued)

    tablet

    • 200mg